← SEC 公告列表 | IPSC SEC 公告 | Century Therapeutics, Inc.（IPSC）

重大事件 即時報告 8-K 2026-06-16

Century Therapeutics 8-K披露首席科學官轉兼職 年薪降至29.6萬美元

於 SEC 網站開啟原文

AI 繁中摘要

Century Therapeutics, Inc.（納斯達克代碼：IPSC）於2026年6月15日提交8‑K表格，披露與首席科學官Chad Cowan博士修訂僱傭協議 🧑‍🔬。 根據經修訂及重述的僱傭協議（A&R Agreement），Cowan博士將繼續擔任首席科學官，但改為兼職形式，年薪由原有水平下調至296,150美元，並按比例享有年度績效目標花紅資格。若其僱傭被公司終止或自行辭職，將可獲取截至離職日止所有已累積但未支付的基薪。 是次安排反映公司因應研發策略調整，削減高層薪酬開支，同時保留核心科研人才的彈性合作模式。投資者需留意此舉對現有臨床項目進度及未來管線開發的潛在影響，尤其是兼職領導可能減慢決策速度。此外，協議完整條款將於2026年6月30日止季度10‑Q申報中附錄披露。
展開英文正文 
false
 0001850119
 
 
 
 
 
 
 
 0001850119
 
 
 2026-06-15
 2026-06-15
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
June 15, 2026

 

 

 

Century Therapeutics, Inc.

(Exact name of registrant as specified in its
charter)

 

 

 

 
 Delaware
  
 001-40498
  
 84-2040295

 
 (State or other jurisdiction of

incorporation or organization)
  
 (Commission File Number)
  
 (I.R.S. Employer

Identification No.)

 
 

 
 
 25
 North 38th Street, 11th Floor

 Philadelphia, Pennsylvania 

  
 19104

 
 (Address of principal executive offices)
  
 (Zip Code)

 
 

Registrant’s telephone number, including
area code: (267) 817-5790

 

Not Applicable

(Former name or former address, if changed since
last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):

 

 
 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of Each Class
  
 Trading Symbol
  
 Name
 of Exchange on Which Registered

 
 Common Stock, par value $0.0001 per share
  
 IPSC
  
 Nasdaq Capital Market

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨

 

 

  

  

 

  

Item 5.02    Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 15, 2026,
Century Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “A&R
Agreement”) with Chad Cowan, Ph.D., the Company’s Chief Scientific Officer. Pursuant to the A&R Agreement, Dr. Cowan
will continue as the Company’s Chief Scientific Officer on a part-time basis, at a reduced annual salary of $296,150 and will be
eligible for an annual performance-based target bonus on a pro-rated basis. In the event of termination of Dr. Cowan’s employment
by the Company or Dr. Cowan’s resignation from the Company, Dr. Cowan will be entitled to all accrued and unpaid base
salary through the date of cessation of his employment.

 

The foregoing description
of the A&R Agreement does not purport to be complete and is qualified in its entirety by reference to the A&R Agreement, which will be
filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

 

  

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
 CENTURY THERAPEUTICS, INC.

 
  
  
  

 
  
 By:
 /s/ Brent Pfeiffenberger, Pharm.D., M.B.A.

 
  
 Name:
 Brent Pfeiffenberger, Pharm.D., M.B.A.

 
  
 Title:
 President, Chief Executive Officer and Chairman of the Board of Directors

 
 

Date: June 16, 2026